Analyst Upgrades: Facebook, AlarmCom, Anacor

Analysts upwardly revised their ratings on Facebook Inc (NASDAQ:FB), AlarmCom Hldg Inc (NASDAQ:ALRM), and Anacor Pharmaceuticals Inc (NASDAQ:ANAC)

Jul 21, 2015 at 9:25 AM
facebook twitter linkedin


Analysts are weighing in on social network giant Facebook Inc (NASDAQ:FB), home security specialist AlarmCom Hldg Inc (NASDAQ:ALRM), and drugmaker Anacor Pharmaceuticals Inc (NASDAQ:ANAC). Here's a quick roundup of today's bullish brokerage notes on FB, ALRM, and ANAC.

  • It looks as if FB just can't be stopped. After closing at its loftiest perch to date yesterday following some upbeat analyst attention, the stock is poised to hit a fresh intraday peak out of today's gate, thanks to a pair of bullish brokerage notes. Specifically, BofA-Merrill Lynch added the security to its U.S. 1 Focus List, while Nomura boosted its price target to $115 from $96. Should Facebook Inc continue to add to its impressive 41% year-over-year advance, another round of price-target hikes could be on the horizon. Currently, the consensus 12-month price target for FB of $98.53 is within a chip shot of last night's settlement at $97.91.

  • Wall Street newcomer ALRM received a bevy of bullish brokerage attention this morning. Chiming in on the stock was William Blair, Stifel, Raymond James, and BofAMerrill-Lynch, which all initiated coverage with the equivalent of a "buy" rating. What's more, the latter three set their price targets in the $21-$22 range, a premium to Monday's close at $18.78. Since going public on June 26, shares of AlarmCom Hldg Inc have added 17%, but appear ready to pare a portion of these gains in today's trading -- down 1.2% at last check.

  • It's been a tremendous year for ANAC, which has surged nearly fivefold to trade at $148.13. In fact, the equity is on pace to notch a fresh record high today -- after tagging an all-time high of $150.41 on Monday -- after Goldman Sachs upped its outlook to "buy" from "neutral" and its price target to $195 from $60. The brokerage firm specifically cited confidence in the company's atopic dermatitis medication, and said it sees "ANAC as an even more attractive acquisition target with Crisaborole de-risked." Should Anacor Pharmaceuticals Inc continue its trek into uncharted territory, shorts may be forced to abandon their losing bets. Short interest accounts for 11.2% of the stock's available float, and it would take almost a week to cover these bearish bets, at ANAC's average daily pace of trading.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!


  
 
Special Offers from Schaeffer's Trading Partners